Argen X Aktie - ARGX

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

555,40

Gebot

553,00

Fragen

556,00

Volumen

90.749

554,00 Tagesbereich 571,20

322,50 52-Wochen-Bereich 658,00

Marktkapitalisierung

36,2B

Handelsende

578,20

Handelsbeginn

568,00

Letzte Trade

555.4

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

64.593

Ausgegebene Aktien

65.178.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

43,46

Gewinn pro Aktie (EPS)

12,78

Erlöse

2,25B

Nettogewinn

833,04M

Sektor

Coml Physical, Biologcl Resh

Branche

Coml Physical, Biologcl Resh

Website

www.argenx.com

Hauptsitz

Amsterdam, North Holland, Nld

Gegründet

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 578,20 €. Over the last year, Argen X shares have traded in a share price range of 322,50 € to 658,00 €.

Argen X currently has 65.178.000 shares in issue. The market capitalisation of Argen X is 37,69 € billion. Argen X has a price to earnings ratio (PE ratio) of 43.46.

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and...

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP...

argenx to Present at TD Cowen 45th Annual Healthcare Conference

February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in...

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-43.4	-7.24782899132	598.8	615	554	128019	593.72658004	DE
4	-74.6	-11.8412698413	630	640.6	554	71037	604.75167074	DE
12	-25.6	-4.40619621343	581	658	554	64593	616.72593394	DE
26	67.8	13.9048400328	487.6	658	456.3	61995	569.55027733	DE
52	199.6	56.0989319843	355.8	658	322.5	60500	481.84247556	DE
156	318.4	134.345991561	237	658	231.8	64700	401.30123252	DE
260	429.4	340.793650794	126	658	93.05	72510	320.00393572	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?

The current share price of Argen X is 555,40 €

How many Argen X shares are in issue?

Argen X has 65.178.000 shares in issue

What is the market cap of Argen X?

The market capitalisation of Argen X is EUR 37,69B

What is the 1 year trading range for Argen X share price?

Argen X has traded in the range of 322,50 € to 658,00 € during the past year

What is the PE ratio of Argen X?

The price to earnings ratio of Argen X is 43,46

What is the cash to sales ratio of Argen X?

The cash to sales ratio of Argen X is 16,07

What is the reporting currency for Argen X?

Argen X reports financial results in USD

What is the latest annual turnover for Argen X?

The latest annual turnover of Argen X is USD 2,25B

What is the latest annual profit for Argen X?

The latest annual profit of Argen X is USD 833,04M

What is the registered address of Argen X?

The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB

What is the Argen X website address?

The website address for Argen X is www.argenx.com

Which industry sector does Argen X operate in?

Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ALEUPEuroplasma	0,02 € (78,57%)	365,72M
MLAZRThe Azur Selection SA	1,13 € (61,43%)	47,07k
ALCYBCybergun	0,0003 € (50,00%)	4,22B
ALJXRArchos	0,241 € (37,71%)	10,35M
ALDOLDolfines	3,21 € (29,96%)	118,41k
DMSBSDiagnostic Medical Systems	0,0015 € (-81,25%)	14,15k
BNBSTonner Drones	0,002 € (-42,86%)	1,61M
TDBSTonner Drones	0,0038 € (-41,54%)	23,76M
BUIBarbara Bui	3,10 € (-24,39%)	1,05k
MLTROTroc de l Ile	2,50 € (-20,38%)	60
ALCYBCybergun	0,0003 € (50,00%)	290,89M
ATOAtos SE	0,0046 € (-6,12%)	201,87M
ALTDTonner Drones	0,027 € (-20,12%)	32,12M
ALEUPEuroplasma	0,02 € (78,57%)	29,84M
TDBSTonner Drones	0,0038 € (-41,54%)	23,76M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Argen X SE (ARGX) Börsenkurse

Argen X SE (ARGX)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Argen X SE

ARGX Neueste Nachrichten

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

ARGX - Frequently Asked Questions (FAQ)

Beweger

ARGX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen